Recursion’s Q1 Revenue Misses as Insiders Sell

Forward-Looking Analysis

For the fiscal second quarter of 2026, market consensus anticipates Recursion Pharmaceuticals to report earnings per share (EPS) of -$0.99 for the full year, indicating continued operational losses. Analyst projections for the specific quarter suggest a significant revenue shortfall, with expectations of $15.78 million, a figure notably higher than the actual $6.47 million reported in Q1 2026. This discrepancy highlights the challenge in meeting top-line targets. Regarding profitability, the company is expected to post negative net income, continuing the trend established in the previous quarter where net income was -$117.50 million. Gross profit is also projected to remain negative, reflecting the high costs associated with its AI-driven drug discovery platform. Institutional sentiment remains mixed; while Morgan Stanley recently upgraded its price target to $5.50 with an "equal weight" rating, Needham & Company maintained a "buy" rating with an $8.00 target. Conversely, Weiss Ratings reaffirmed a "sell" rating. JPMorgan Chase lowered its target from $11.00 to $10.00 but retained an "overweight" rating. The average analyst rating sits at "Hold" with an average price target of $8.10, suggesting limited near-term upside despite long-term AI biotech potential.

Historical Performance Review

Recursion’s 2026Q1 results demonstrated significant operational challenges. The company reported revenue of $6.47 million, falling well short of the $15.78 million analyst expectation and representing a 56.8% year-over-year decline. Net income stood at -$117.50 million, driven by a negative net margin of 842.95% and a negative return on equity of 54.33%. The company posted an EPS of -$0.22, which surprisingly beat the consensus estimate of -$0.30 by $0.08. However, gross profit was recorded at -$6.02 million, underscoring the substantial costs incurred in its digital biology platform operations during the quarter.

Additional News

Institutional ownership of Recursion Pharmaceuticals remains robust at 89.06%, with several major investors increasing their stakes. Vanguard Group Inc. raised its position by 18.6% in the fourth quarter, now holding 47,187,759 shares valued at approximately $193 million. Hsbc Holdings PLC significantly boosted its holdings by 537.3%, while First Trust Advisors LP increased its position by 15.2% in the first quarter of 2026. Despite this institutional confidence, insider selling activity was notable. Director Blake Borgeson sold 40,000 shares at an average price of $3.96 in July, and CEO Najat Khan sold 23,588 shares at $3.58 in June. Both transactions occurred under pre-arranged Rule 10b5-1 trading plans. Over the last 90 days, insiders sold a total of 131,937 shares valued at $486,974. Recursion’s stock has outperformed the S&P 500, with a year-to-date return of 26.65% compared to the benchmark's 9.41%, and a one-year return of 49.58%. The stock currently trades with a market capitalization of $1.59 billion and a debt-to-equity ratio of 0.01, indicating a strong balance sheet despite negative earnings.

Summary & Outlook

Recursion Pharmaceuticals exhibits a financially strained profile with negative gross profits and substantial net losses, yet maintains a pristine balance sheet with minimal debt. The primary growth catalyst is its proprietary AI-driven "Recursion OS" platform, which promises to revolutionize drug discovery efficiency. However, the significant miss in Q1 revenue against expectations raises immediate risks regarding commercial validation and cost management. While institutional investors remain bullish, recent insider selling and persistent unprofitability warrant caution. The outlook is neutral-to-bearish in the short term due to execution risks in revenue generation, but long-term prospects depend entirely on the successful translation of AI capabilities into tangible therapeutic milestones and revenue streams. Investors should monitor upcoming clinical trial updates and partnership announcements for signs of fundamental improvement.